BioSpace News Archive

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022.

NeoDynamics AB today announced the appointment of current board member Matt Colpoys as head of the company’s US subsidiary.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS).

Quest Diagnostics (NYSE:DGX), the nation’s leading provider of diagnostic information services, has been awarded a group purchasing agreement for its laboratory stewardship solution with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company uniting an alliance of hospitals, health systems and providers.

Biovica International Biovica, active in cancer diagnostics, announces that the company has employed a sales team of total of eight people to secure a fast and smooth launch and the further commercial development of DiviTum® TKa on the US market.

Aziyo Biologics, Inc. today announced the pricing of its underwritten public offering of 2,350,000 shares of its common stock at a public offering price of $4.75 per share, before deducting underwriting discounts and commissions.

Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort MedBot”) announced that on November 22nd, 2022 MicroPort NaviBot International, LLC in recent collaboration with MicroPort Orthopedics has completed the first clinical use of the SkyWalker™ Robotic System in the United States.

Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the first patient has been dosed in the Phase 1/2 dose-escalation and expansion study of Q901 in patients with advanced solid tumors.

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, announces the launch of the ExactaMix Pro Automated Compounder, which is expected to be available to customers in the United States in early 2023.